|
08/30/23
|
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
|
|
|
08/08/23
|
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
|
|
|
06/20/23
|
Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)
|
|
|
05/08/23
|
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
|
|
|
04/12/23
|
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
|
|
|
04/10/23
|
Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
|
|
|
02/27/23
|
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
|
|
|
02/22/23
|
Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
|
|
|
02/15/23
|
Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™
|
|
|
01/25/23
|
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
|
|